Mark Magbanua, PhD

Title(s)Professional Researcher, Laboratory Medicine
SchoolSchool of Medicine
Address2340 Sutter Street, #S433
San Francisco CA 94115
Phone415-514-3969
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California San FranciscoPostdoctoral ReseacherHematology Oncology
    University of California DavisPhDPlant Biology
    University of California DavisMScInternational Agricultural Development
    Kansas State University MScPlant Pathology
    University of the Philippines at Los BanosBSc Biology/GeneticsInstitute of Biological Sciences
    Collapse Awards and Honors
    2012• ASCO Foundation Merit Award, Genitourinary Cancers Symposium
    2011• ASCO Foundation Merit Award, Breast Cancer Symposium
    2010• AACR Minority Scholar Award in Cancer Research, SABCS
    2009• ASCO Foundation Merit Award, Genitourinary Cancers Symposium
    2009• ASCO Foundation Merit Award, Breast Cancer Symposium
    2008• Best Scientific Poster Award, Breast Oncology Program, UC San Francisco
    2003• Outstanding Graduate Teaching Award, UC Davis
    2002• Professors for the Future Fellowship

    Collapse Research 
    Collapse Research Activities and Funding
    Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer
    NIH R01CA255442Dec 3, 2020 - Nov 30, 2025
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. NPJ Breast Cancer. 2024 Aug 21; 10(1):75. Stover DG, Salgado R, Savenkov O, Ballman K, Mayer EL, Magbanua MJM, Loi S, Vater M, Glover K, Watson M, Wen Y, Symmans WF, Perou C, Carey LA, Partridge AH, Rugo HS. PMID: 39169033; PMCID: PMC11339397.
      View in: PubMed   Mentions:
    2. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2444-2451. Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 38470545; PMCID: PMC11147708.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes. Cancers (Basel). 2024 May 15; 16(10). Magbanua MJM, Li W, van 't Veer LJ. PMID: 38791958; PMCID: PMC11120531.
      View in: PubMed   Mentions:
    4. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis. NPJ Breast Cancer. 2024 Feb 26; 10(1):17. Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA. PMID: 38409268; PMCID: PMC10897340.
      View in: PubMed   Mentions:
    5. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med. 2023 12 19; 4(12):101312. Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. PMID: 38086377; PMCID: PMC10772394.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Jan; 203(2):197-204. Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS. PMID: 37815684; PMCID: PMC10787873.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    7. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4. Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 37146605; PMCID: PMC10330514.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    8. Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression. bioRxiv. 2023 Mar 29. Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N. PMID: 37034710; PMCID: PMC10081280.
      View in: PubMed   Mentions:
    9. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Res Treat. 2023 Apr; 198(2):383-390. Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A. PMID: 36689092; PMCID: PMC10290540.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023 01 21; 22(1):15. Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van 't Veer LJ, Magbanua MJM. PMID: 36681803; PMCID: PMC9862574.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    11. Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy. Cancers (Basel). 2022 Sep 13; 14(18). Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, Van't Veer LJ, Hylton NM. PMID: 36139594; PMCID: PMC9497087.
      View in: PubMed   Mentions: 7  
    12. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. PMID: 35623341; PMCID: PMC9426306.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    13. Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Front Oncol. 2022; 12:802579. Magbanua MJM, Gumusay O, Kurzrock R, van 't Veer LJ, Rugo HS. PMID: 35372077; PMCID: PMC8964955.
      View in: PubMed   Mentions: 5  
    14. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer. 2021 Sep 06; 7(1):113. Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS. PMID: 34489453; PMCID: PMC8421499.
      View in: PubMed   Mentions: 9  
    15. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 04 06; 113(4):443-452. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. PMID: 32770247; PMCID: PMC8023821.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    16. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer. 2021 Mar 25; 7(1):32. Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L. PMID: 33767190; PMCID: PMC7994408.
      View in: PubMed   Mentions: 24  
    17. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021 02; 32(2):229-239. Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ. PMID: 33232761; PMCID: PMC9348585.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    18. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2020; 6:48. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer L. PMID: 33083527; PMCID: PMC7532145.
      View in: PubMed   Mentions: 17  
    19. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clin Cancer Res. 2020 09 15; 26(18):4911-4920. Magbanua MJM, Savenkov O, Asmus EJ, Ballman KV, Scott JH, Park JW, Dickler M, Partridge A, Carey LA, Winer EP, Rugo HS. PMID: 32586939; PMCID: PMC7501177.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    20. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. Clin Cancer Res. 2019 09 01; 25(17):5388-5397. Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW. PMID: 31142502; PMCID: PMC6726564.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    21. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018; 4:31. Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. PMID: 30211312; PMCID: PMC6125436.
      View in: PubMed   Mentions: 17  
    22. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018 06 01; 110(6):560-567. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. PMID: 29659933.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCells
    23. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res. 2018 03 15; 24(6):1486-1499. Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. PMID: 29311117; PMCID: PMC5856614.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    24. Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Res. 2017 08 15; 77(16):4530-4541. Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters BA. PMID: 28811315.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    25. Automated Microfluidic Filtration and Immunocytochemistry Detection System for Capture and Enumeration of Circulating Tumor Cells and Other Rare Cell Populations in Blood. Methods Mol Biol. 2017; 1634:119-131. Pugia M, Magbanua MJM, Park JW. PMID: 28819845.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    26. Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration. Adv Exp Med Biol. 2017; 994:119-131. Pugia M, Magbanua MJM, Park JW. PMID: 28560671.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    27. Enumeration of Circulating Tumor Cells and Disseminated Tumor Cells in Blood and Bone Marrow by Immunomagnetic Enrichment and Flow Cytometry (IE/FC). Methods Mol Biol. 2017; 1634:203-210. Magbanua MJM, Solanki TI, Ordonez AD, Hsiao F, Park JW. PMID: 28819853.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    28. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat. 2016 12; 160(3):411-424. Lee JS, Magbanua MJM, Park JW. PMID: 27761678.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    29. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):339-49. Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. PMID: 26520840.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    30. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. PMID: 26496203; PMCID: PMC4619669.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    31. Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget. 2015 Oct 13; 6(31):30715-29. Magbanua MJ, Das R, Polavarapu P, Park JW. PMID: 26378808; PMCID: PMC4741563.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    32. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ. PMID: 26021444; PMCID: PMC4479083.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    33. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015 Mar 31; 15:206. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. PMID: 25884197; PMCID: PMC4399150.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCellsCTClinical Trials
    34. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium. PMID: 25524311.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    35. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. PMID: 25432738; PMCID: PMC4698170.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    36. Advances in genomic characterization of circulating tumor cells. Cancer Metastasis Rev. 2014 Sep; 33(2-3):757-69. Magbanua MJ, Park JW. PMID: 24867683.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    37. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. PMID: 25030168; PMCID: PMC4487551.
      View in: PubMed   Mentions: 309     Fields:    Translation:HumansAnimalsCells
    38. Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors. Genom Data. 2014 Dec; 2:60-2. Magbanua MJ, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Melisko M, Park JW. PMID: 26484071; PMCID: PMC4535622.
      View in: PubMed   Mentions: 6  
    39. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control. 2014 Apr; 25(4):515-23. Magbanua MJ, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. PMID: 24504435; PMCID: PMC3990413.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    40. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013 Dec 01; 73(23):7134-43. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW. PMID: 24142343.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    41. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol. 2013 Oct; 14(11):1112-1120. Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G, Marlin R, Frenda SJ, Magbanua MJM, Daubenmier J, Estay I, Hills NK, Chainani-Wu N, Carroll PR, Blackburn EH. PMID: 24051140.
      View in: PubMed   Mentions: 142     Fields:    Translation:Humans
    42. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191; PMCID: PMC3790192.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    43. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods. 2013 Dec 01; 64(2):114-8. Magbanua MJ, Park JW. PMID: 23896286.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    44. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013 Jan 01; 73(1):30-40. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. PMID: 23135909; PMCID: PMC4085329.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    45. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012 Feb 28; 12:78. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW. PMID: 22373240; PMCID: PMC3395839.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    46. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. PLoS One. 2011; 6(9):e24004. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. PMID: 21912659; PMCID: PMC3164676.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    47. Differential expression of thrombospondin (THBS1) in tumorigenic and nontumorigenic prostate epithelial cells in response to a chromatin-binding soy peptide. Nutr Cancer. 2011; 63(4):623-36. Galvez AF, Huang L, Magbanua MM, Dawson K, Rodriguez RL. PMID: 21526452; PMCID: PMC3210036.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    48. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control. 2011 Jan; 22(1):141-50. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M, Hughes-Fulford M, Haqq C, Carroll PR. PMID: 21103921; PMCID: PMC3002170.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    49. A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genomics. 2009 Jul 20; 10:326. Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM. PMID: 19619282; PMCID: PMC2724417.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    50. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol. 2008 Nov; 9(11):1048-57. Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, Kemp C, Magbanua MJ, Marlin R, Yglecias L, Carroll PR, Blackburn EH. PMID: 18799354.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCellsCTClinical Trials
    51. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008 Jun 17; 105(24):8369-74. Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C, Mattie MD, Marlin R, Simko J, Shinohara K, Haqq CM, Carroll PR. PMID: 18559852; PMCID: PMC2430265.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCells
    Mark's Networks
    Concepts (195)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (57)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.